Impact of a five-dimensional framework on R&D productivity at AstraZeneca
| Autor: | Mark J. Anderton, Anthony Johnson, Menelas N. Pangalos, Paul Morgan, David J. Nicholls, Stefan Platz, Ulf G. Eriksson, J. Carl Barrett, Jerome T. Mettetal, Ruth March, Mark Fidock, Dean G. Brown, James Matcham, Steve Rees, Michael A. Snowden, Simon Lennard, Bengt Hamrén |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Research design Biomedical Research Process management Drug Industry media_common.quotation_subject MEDLINE Organizational culture Efficiency Efficiency Organizational 03 medical and health sciences Drug Discovery Humans Quality (business) Safety testing Productivity Decision Making Organizational media_common Pharmacology Clinical Trials as Topic Research Cornerstone Drugs Investigational General Medicine Organizational Culture 030104 developmental biology Research Design Nomination Psychology |
| Zdroj: | Nature Reviews Drug Discovery. 17:167-181 |
| ISSN: | 1474-1784 1474-1776 |
| DOI: | 10.1038/nrd.2017.244 |
| Popis: | In 2011, AstraZeneca embarked on a major revision of its research and development (R&D) strategy with the aim of improving R&D productivity, which was below industry averages in 2005-2010. A cornerstone of the revised strategy was to focus decision-making on five technical determinants (the right target, right tissue, right safety, right patient and right commercial potential). In this article, we describe the progress made using this '5R framework' in the hope that our experience could be useful to other companies tackling R&D productivity issues. We focus on the evolution of our approach to target validation, hit and lead optimization, pharmacokinetic/pharmacodynamic modelling and drug safety testing, which have helped improve the quality of candidate drug nomination, as well as the development of the right culture, where 'truth seeking' is encouraged by more rigorous and quantitative decision-making. We also discuss where the approach has failed and the lessons learned. Overall, the continued evolution and application of the 5R framework are beginning to have an impact, with success rates from candidate drug nomination to phase III completion improving from 4% in 2005-2010 to 19% in 2012-2016. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink